QH103 Cell Injection for the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

Anhui Provincial Hospital (Other)
Overall Status
CT.gov ID

Study Details

Study Description

Brief Summary

This is a single-arm, single-center, interventional, dose-escalation clinical study designed to evaluate the safety and tolerability of QH103 Cell Injection in the treatment of patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

To evaluate the safety and tolerability of QH103 Cell Injection in the treatment of relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia, and to evaluate dose-limiting toxicity and maximum tolerated dose.

Study Design

Study Type:
Anticipated Enrollment :
10 participants
Intervention Model:
Single Group Assignment
None (Open Label)
Primary Purpose:
Official Title:
A Dose-escalation Clinical Study of QH103 Cell Injection (CD19 CAR-γδT Cell Injection) in Patients With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL).
Anticipated Study Start Date :
Sep 30, 2023
Anticipated Primary Completion Date :
Jul 3, 2025
Anticipated Study Completion Date :
Jul 3, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Patients with relapsed/refractory CD19-positive B-cell acute lymphoblastic leukemia

A conditional chemotherapy regimen of fludarabine and cyclophosphamide will be administered, followed by investigational therapy, QH103 Cells

Biological: QH103 Cell Injection
dose escalation (3+3) : dose 1 (3×10^8CAR+cells) ,dose 2 (1 × 10^9 CAR+cells),dose 3 (3 × 10^9CAR+cells)

Drug: Fludarabine
Intravenous fludarabine on days-5~-2,the infusion dose is adjusted according to the subject's condition
Other Names:
  • Fludarabine Phosphate for Injection
  • Drug: Cyclophosphamide
    Intravenous cyclophosphamide on days -5~-3, the infusion dose is adjusted according to the subject's condition
    Other Names:
  • Cyclophosphamide for Injection
  • Outcome Measures

    Primary Outcome Measures

    1. Incidence of Adverse Events (AEs) [12 months]

      AE is defined as any adverse medical event from the date of leukapheresis to 12 months after QH103 infusion. Among them, cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria, graft-versushost disease (GVHD) according to criteria defined by the Mount Sinai Acute GVHD International Consortium. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0

    2. Incidence of Dose-Limiting Toxicities (DLTs) [First infusion date of QH103 cells to 28 days end cell infusion]

      DLT was defined as QH103 Cells-related events with onset within first 28 days following infusion: The development of Grade (G) III-IV acute GVHD according to the Mount Sinai Acute GVHD International Consortium criteria; The development of G3 or higher grade CRS lasting > 2 weeks; Any QH103 cells-related AE requiring intubation; All G4 non-hematologic toxicities. Symptoms of GVHD include but are not limited to skin rash, enterocolitis with diarrhea, liver dysfunction with jaundice, fever, weight loss, etc.

    3. Maximum tolerated dose (MTD) [28 days]

      MTD is defined as the highest dose level of less than or equal to 2 DLT among the 6 subjects finally determined.

    Secondary Outcome Measures

    1. Overall Survival (OS) [12 months]

      OS is defined as the time from QH103 cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

    2. Progression Free Survival (PFS) [12 months]

      PFS is defined as the time from the QH103 cells infusion date to the date of disease progression assessed by investigators assessment, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at their last evaluable disease assessment date.

    3. Pharmacokinetics: Persistence of the QH103 cells [28 days]

      Persistence of the QH103 cells assessed by number in peripheral blood.

    4. Pharmacodynamics: Peak level of cytokines in serum [28 days]

      The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α) etc. Peak was defined as the maximum post-baseline level of the cytokine.

    5. Overall Response Rate(ORR) [12 months]

      Proportion of subjects with CR (complete response) and CRi (complete response with incomplete hemocyte recovery)

    Eligibility Criteria


    Ages Eligible for Study:
    14 Years and Older
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    1. Age ≥14 years, gender is not limited;

    2. Patients with clinically diagnosed relapsed/refractory B-ALL (except those presenting with extramedullary disease only), including any of the following:

    3. Failure to obtain CR after 2 cycles of standard chemotherapy;

    4. First induction of CR, but duration of CR is ≤12 months;

    5. Relapsed/refractory B-ALL that has failed to respond to the first or multiple salvage treatments;

    6. Relapse after hematopoietic stem cell transplantation, including hematological relapse and positive micro residual disease (MRD).

    7. Cytological or histological confirmation of tumor cell immunophenotyping as CD19 positive;

    8. Bone marrow with a ratio of ≥5% primitive/naïve lymphocytes (morphology);

    9. Expected survival time of more than 3 months;

    10. Eastern Cooperative Oncology Group (ECOG) score of 0-2;

    11. Vital organ function meets the following requirements: left ventricular ejection fraction ≥50% on echocardiography; serum creatinine≤1.5 × upper limit of normal range (ULN); glutamine aminotransferase, aspartate aminotransferase ≤3 times ULN, total bilirubin ≤1.5 times ULN;

    12. Pregnancy tests for women of childbearing age should be negative, and both men and women should agree to use effective contraception during treatment and for the following 1 year.

    13. Toxicity of prior antitumor therapy ≤ grade 1 (according to CTCAE version 5.0) or acceptable inclusion/exclusion criteria level.

    14. No significant hereditary disease;

    15. Be able to understand the requirements and matters of the trial and be willing to participate in the clinical study as required;

    16. Sign the trial informed consent form.

    Exclusion Criteria:
    1. with uncontrolled active central nervous system leukemia (CNSL) or a history of epilepsy, cerebrovascular disease

    2. Pregnant or lactating women, or those who do not consent to the use of the drug during and within 1 year after treatment;

    3. Other malignant tumors not in remission;

    4. with primary immunodeficiency or autoimmune diseases requiring immunosuppressive therapy;

    5. Patients who have received immune cell therapy within 6 months prior to enrollment and donor lymphocyte infusion within 6 weeks prior to enrollment.

    6. Patients with confirmed positive serum anti-FMC63 and DSA reactions;

    7. Patients who have participated in other clinical trials within 4 weeks prior to enrollment;

    8. Uncontrolled infectious or other serious diseases, including but not limited to infections (Human Immunodeficiency Virus, acute or chronic active hepatitis B or hepatitis C), congestive heart failure, unstable angina pectoris cardiac arrhythmias, or conditions that the attending physician considers to be an unpredictable risk;

    9. Uncontrollable plasma fluid, such as large pleural effusions or ascites;

    10. History of stroke or intracranial hemorrhage within 3 months prior to enrollment;

    11. Major surgery or trauma within 28 days prior to enrollment, or major side effects from which you have not recovered;

    12. History of allergy to any of the ingredients in the cellular product;

    13. Inability to understand or unwillingness to sign the informed consent form;

    14. Other reasons deemed by the investigator to be unsuitable for the clinical trial.

    Contacts and Locations


    Site City State Country Postal Code
    1 Anhui Provincial Hospital Hefei Anhui China 230036

    Sponsors and Collaborators

    • Anhui Provincial Hospital


    • Principal Investigator: Xiaoyu Zhu, Ph.D, Director of Hematology Department, Anhui Provincial Hospital

    Study Documents (Full-Text)

    None provided.

    More Information


    None provided.
    Responsible Party:
    Xiaoyu Zhu, Director of Hematology Department, Anhui Provincial Hospital
    ClinicalTrials.gov Identifier:
    Other Study ID Numbers:
    • QH10302-B-01(0)
    First Posted:
    Sep 28, 2023
    Last Update Posted:
    Sep 28, 2023
    Last Verified:
    Sep 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Xiaoyu Zhu, Director of Hematology Department, Anhui Provincial Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 28, 2023